Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

The report provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs. BROOKLYN, NY, UNITED ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

The global prostate cancer market is projected to be valued at USD 12.9 billion in 2025 and is expected to reach USD 29.2 billion by 2035, registering a CAGR of 8.5% during the forecast period, driven ...

Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

While biopharmaceutical technologies have made substantial strides in treating diseases, drug research and development ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...